Publications by authors named "Mark Fineman"

Claim this Profile
A
Additive effects of GLY-200 (oral pharmacologic duodenal exclusion therapy) and GLP-1R agonist in obesity management.
Taylor L Carlson, Mark Fineman, Stace Kernodle, Chelsea R Hutch, Christine Bryant

Mol Metab· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GLY-200, an oral pharmacologic duodenal exclusion drug, resulted in positive effects on glucose, lipids and bodyweight in patients with type 2 diabetes: Results of a randomized, double-blind placebo-controlled trial.
Christine L N Bryant, Kevin Colbert, Marcus Hompesch, SuZanne Chaves, Ashish Nimgaonkar, Mark S Fineman

Diabetes Obes Metab· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 3, 56-week, randomised, double-blind, placebo-controlled study (OA-11) utilising patient-reported and radiographic outcomes evaluating the efficacy and safety of a lorecivivint injection in patients with moderate to severe knee osteoarthritis.
Yusuf Yazici, Jeyanesh R S Tambiah, Christopher J Swearingen, Jonathan Britt, Sarah Kennedy, Mark S Fineman

Clin Exp Rheumatol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 3, 28-week, multicentre, randomised, double-blind, placebo-controlled trial (OA-10) to evaluate the efficacy and safety of a single injection of lorecivivint in the target knee joint of moderately to severely symptomatic osteoarthritis patients.
Yusuf Yazici, Jeyanesh R S Tambiah, Christopher J Swearingen, Victor A Lopez, Sarah Kennedy, Mark S Fineman

Clin Exp Rheumatol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, and Pharmacokinetics of Same-Knee Intra-Articular Injection of Corticosteroid and Lorecivivint Within 7 Days: An Open-Label, Randomized, Parallel-Arm Study.
Mark S Fineman, Timothy E McAlindon, Christian Lattermann, Christopher J Swearingen, Sarah Kennedy

Rheumatol Ther· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human study of a pharmacological duodenal exclusion therapy shows reduced postprandial glucose and insulin and increased bile acid and gut hormone concentrations.
Mark S Fineman, Christine L N Bryant, Kevin Colbert, Thomas H Jozefiak, John S Petersen

Diabetes Obes Metab· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes.
Robert R Henry, Juan P Frias, Brandon Walsh, Sharon Skare, John Hemming, Mark Fineman

PLoS One· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metformin-associated lactic acidosis: Moving towards a new paradigm?
Thomas A Bicsak, Brandon Walsh, Mark Fineman

Diabetes Obes Metab· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spinal Disinhibition in Experimental and Clinical Painful Diabetic Neuropathy.
Andrew G Marshall, Corinne Lee-Kubli, Shazli Azmi, Michael Zhang, Maryam Ferdousi, Mark S Fineman

Diabetes· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials.
Ralph A DeFronzo, John B Buse, Terri Kim, Colleen Burns, Sharon Skare, Mark Fineman

Diabetologia· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies.
John B Buse, Ralph A DeFronzo, Julio Rosenstock, Terri Kim, Colleen Burns, Mark Fineman

Diabetes Care· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.
John B Buse, Michael Nauck, Thomas Forst, Wayne H-H Sheu, Sylvia K Shenouda, Mark Fineman

Lancet· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment.
Mark S Fineman, K F Mace, M Diamant, T Darsow, B B Cirincione

Diabetes Obes Metab· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing.
Mark Fineman, Shawn Flanagan, Kristin Taylor, Maria Aisporna, Larry Z Shen

Clin Pharmacokinet· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.
Jaret Malloy, Edmund Capparelli, Michael Gottschalk, Xuesong Guan, Prajakti Kothare, Mark Fineman

Clin Ther· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus.
Prajakti A Kothare, Helle Linnebjerg, Yoshitaka Isaka, Kazunori Uenaka, Ayuko Yamamura, Mark Fineman

J Clin Pharmacol· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes.
Helle Linnebjerg, Soomin Park, Prajakti A Kothare, Michael E Trautmann, Kenneth Mace, Mark Fineman

Regul Pept· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes.
Patric Nelson, Terri Poon, Xuesong Guan, Catherine Schnabel, Matthew Wintle, Mark Fineman

Diabetes Technol Ther· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of an oral drug (acetaminophen) administered at various times relative to subcutaneous injection of pramlintide in subjects with type 2 diabetes.
Terrie A Kellmeyer, Nicole C Kesty, Yan Wang, Juan P Frias, Mark S Fineman

J Clin Pharmacol· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
Dennis Kim, Leigh MacConell, Dongliang Zhuang, Prajakti A Kothare, Michael Trautmann, Mark Fineman

Diabetes Care· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes.
Frauke Fehse, Michael Trautmann, Jens J Holst, Amy E Halseth, Nuwan Nanayakkara, Mark S Fineman

J Clin Endocrinol Metab· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study.
Terri Poon, Patric Nelson, Larry Shen, Michael Mihm, Kristin Taylor, Mark Fineman

Diabetes Technol Ther· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects.
Erich Blase, Kristin Taylor, Hong-Ye Gao, Matthew Wintle, Mark Fineman

J Clin Pharmacol· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.
David M Kendall, Matthew C Riddle, Julio Rosenstock, Dongliang Zhuang, Dennis D Kim, Mark S Fineman

Diabetes Care· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
Ralph A DeFronzo, Robert E Ratner, Jenny Han, Dennis D Kim, Mark S Fineman

Diabetes Care· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis